[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meningitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meningitis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,58,101,134,162,190,220,316,348,367,390,412,442,468,503],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100638958","immune-mitochondrial-correction-in-military-recruits-100638958",false,"NCT07622147","Immune-Mitochondrial Correction in Military Recruits","A Parallel-Group, Participant-Blinded Comparative Trial of an Immuno-Mitochondrial Correction Strategy (Sodium Nucleinate + Magnesium\u002FPyridoxine + Vitamin D3 5000 IU) Versus Standard Multivitamin Prophylaxis to Reduce Respiratory Infection Incidence in Male Military Recruits During the 6-Month Adaptation Period","IMMU-MITO","Inclusion Criteria:\n\n* Male military recruits aged 18-27 years\n* Starting initial military training at the Military Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan (Almaty)\n* Signed informed consent\n* No acute infectious diseases at enrollment\n* Willingness to comply with the study protocol for 6 months\n* Absence of any exclusion criteria\n\nExclusion Criteria:\n\n* Chronic immunodeficiency states (HIV infection, congenital immunodeficiencies, current immunosuppressive therapy)\n* Severe chronic diseases in decompensation stage (diabetes mellitus, renal failure, hepatic failure, heart failure)\n* Allergy or hypersensitivity to any components of the study interventions (multivitamin, sodium nucleinate, magnesium, vitamin B6, vitamin D)\n* Use of vitamin-mineral complexes or immunomodulators within the last 3 months prior to enrollment\n* Hypercalcemia (serum calcium \\>2.6 mmol\u002FL) or history of urolithiasis\n* Hypermagnesemia (serum magnesium \\>1.1 mmol\u002FL)\n* Sarcoidosis or other granulomatous diseases\n* Refusal or inability to provide informed consent",true,"MALE","18 Years","27 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn if a new immune-mitochondrial correction strategy works better than standard vitamins to prevent infections in young male military recruits during their first 6 months of service.\n\nThe main questions it aims to answer are:\n\n1. Does the new strategy lower the number of recruits who get infections (like colds, flu, or pneumonia) over 6 months?\n2. Does the new strategy improve how well the immune cells work, specifically their mitochondria (the power source inside cells)?\n\nResearchers will compare:\n\n* Control group (100 participants): Standard multivitamin taken once a day for 30 days\n* Experimental group (100 participants): New strategy (sodium nucleinate, magnesium, vitamin B6, and vitamin D 5000 IU) taken as 3 tablets once a day for 30 days to see if the new strategy lowers infection rates more than standard vitamins.\n\nWho can take part:\n\nHealthy male military recruits aged 18-27 years who are starting their initial training at the Military Clinical Hospital in Almaty, Kazakhstan.\n\nWhat participants will do:\n\nParticipants will be placed into one of the two groups by chance (like flipping a coin). They will:\n\n* Take study pills once a day for 30 days\n* Have blood draws 3 times over 6 months (baseline, 1 month, and 6 months)\n* Have daily health checks by medical staff\n* Complete quality of life questionnaires\n\nWhat we will measure:\n\n* Number of participants who get infections during 6 months\n* How well the mitochondria in immune cells work (from blood samples)\n* Immune system status\n* Stress and adaptation levels\n* Vitamin D and other blood markers\n\nRisks and benefits:\n\nThe risks are very low. Participants may have mild discomfort or a small bruise from blood draws. All study pills are approved and registered in Kazakhstan.\n\nThere is no direct benefit to participants, but they will receive extra medical monitoring. The indirect benefit is helping develop a better prevention program to protect future recruits.\n\nWhere the study is taking place:\n\nMilitary Clinical Hospital of the Ministry of Defense of the Republic of Kazakhstan, Almaty, Kazakhstan.\n\nStudy duration:\n\nJanuary 2027 to December 2028.",[29,30,31,32,33,34,35],"Respiratory Tract Infections (RTI)","Meningitis","Primary Prevention\u002FMethods","Primary Prevention","Mitochondrial Biomarkers","Immuno-monitoring","Immuno-modulation",[37,38,39,40,41,42,43,44,45],"Military recruits","Infection prevention","Immunocorrection","Mitochondrial function","Sodium nucleinate","Vitamin D","Respiratory infections","Stress adaptation","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-24",{"date":49,"type":50},"2026-06-29","ACTUAL",{"date":52,"type":23},"2027-01-01",{"date":54,"type":23},"2028-12",{"name":56,"class":57},"MIPO Clinic","OTHER",{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":24,"phases":69,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":100},"100469490","regulating-emotions-and-behaviors-after-brain-injury-100469490","NCT05393492","Regulating Emotions and Behaviors After Brain Injury","Dialectical Behavior Therapy for Challenging Behaviors and Emotional Distress After Acquired Brain Injury : a Pilot Study","GREMO-LCA","Eligibility Criteria: \\* (Limit: 15,000 characters)\n\nSummary criteria for participant selection.\n\nMain eligibility criteria\n\nGREMO patients :\n\n* Inclusion criteria:\n\n  * Persons with acquired brain injury regardless of the type or location of the injury\n  * Age between 18 and 68\n  * Over 18 months since the acquired brain injury (or 6 month if mild traumatic brain injury)\n  * Challenging behaviors or emotional dysregulation or high level of anxiety \u002F depression or family's complaints about emotional dysregulation\n  * Secondary or exacerbated by an acquired brain injury\n  * Causing important suffering for themselves or their families\n  * Being affiliated to a social security\n  * Fluent in French\n  * Being able to understand goals and risks and to give a dated and signed consent\n* Exclusion criteria:\n\n  * Clinically evident severe lack of insight, lack of abstract reasoning, or severe anosognosia\n  * Patients without any complaints\n  * Severe cognitive impairments, aphasia or intellectual impairments that doesn't allow to understand DBT skills, questionnaires or group intreactions\n  * Non fluent in French\n  * Associated brain degenerative disease\n  * Cancerous brain injury with uncertain progression\n  * Non-stabilized psychotic disorder\n  * Following a third wave cognitive behavioral therapy during the research study (for example : acceptance and commitment therapy)\n\nControls without brain injury\n\n* Inclusion criteria :\n\n  * Being 18 years old or more\n  * Without brain injury\n* Exclusion criteria :\n\n  * Non fluent in French\n  * History of brain injury or brain disease\n  * History of psychiatric disorder\n  * Personality disorder\n  * GREMO patient's family member living together\n  * Psychologist, neuropsychologist or people with an emotional regulation knowledge linked to their profession\n  * Being under guardianship or curatorship\n  * Being pregnant or breastfeeding\n\nGREMO patients' family members\n\n* Inclusion criteria :\n\n  * Being 18 years old or more\n  * GREMO patient's family member\n  * Living with a GREMO patient\n  * Agreeing to rate an emotion-behavior-skills diary cards\n* Exclusion criteria :\n\n  * GREMO patient's refusal for their family member to participate\n  * Non fluent in French\n  * Brain injury or brain disease\n  * Major lack of insight\n  * Being under trusteeship or curatorship\n\nQualitative research ABI patients and families\n\n* Inclusion criteria :\n\n  * Person with ABI attending the same medico-social service as GREMO patients\n  * Ineligible for GREMO patients group (participation refusal, major insight difficulty…)\n  * Agreeing to talk about their free will or spirituality\n* Exclusion criteria :\n\n  * Aphasia or dysarthria not allowing understandable recording\n  * Impossibility to understand oral questions\n  * Non fluent in French","ALL",{"count":68,"type":23},77,[26],"After acquired brain injury (ABI), persons can experience emotional and behavioral difficulties, that can be painful both for the person and his\u002Fher family. This clinical study aims at measuring the effectiveness of a third wave cognitive behavioral therapy called \"dialectical behavior therapy\" (DBT). DBT aims at teaching persons emotion regulation skills, interpersonal effectiveness skills, mindfulness and distress tolerance skills through group and individual sessions.\n\nThe study's hypothesis is that DBT, in an adapted format for persons with ABI can lead to\n\n* a better quality of life, emotional and behavioral regulation, and self-esteem\n* decrease in problematic behaviors\n* progress in life goals\n* increase post traumatic growth and spirituality\n* better family functioning and lesser burden for care givers\n* experiencing more emotions and more free will\n\n  45 persons with an ABI sustained more than 18 month back, will follow a 3 phases, follow-up with care as usual for 5 months, followed by 5 months of DBT, followed by 5 months of care as usual + DBT monthly sessions.\n\nSelf- and family-questionnaire will explore quality of life, emotional regulation, self-esteem, stress, anxiety, cognitive difficulties, family functioning and coping, post traumatic growth and spirituality and will be compared across the 3 phases. Results will be analyzed at a group level but also at an individual level (each patient separately) to test for decrease in unwanted behaviors and at a dyadic level (the person and his\u002Fher spouse) to test for the mutual effect of regulating emotions. Persons' memories will by analyzed at 3 time points by a linguistic analysis, and experience of free will after ABI will be analyzed by transcribed narratives of participants.",[72,73,74,75,76,30],"Acquired Brain Injury","Stroke\u002F Cerebrovascular Accident (Ischemic or Hemorrhagic)","Brain Tumor (After Recovery)","Encephalitis","Cerebral Anoxia",[78,79,80,81,82,83,84,85,86,87,88,89,90],"brain injury","dialectical behavior therapy","emotions","emotional dysregulation","behavioral disorders","spirituality","challenging behaviors","linguistic markers","emotional distress","family burden","free will","interpretative phenomenological analysis","single-case experimental design","RECRUITING","2026-06-05",{"date":94,"type":50},"2026-06-09",{"date":96,"type":50},"2022-05-19",{"date":54,"type":23},{"name":99,"class":57},"University Hospital, Strasbourg, France",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100595055","acute-treatment-and-long-term-assessment-of-adult-infectious-meningitis-100595055","NCT07027475","Acute Treatment and Long-term Assessment of Adult Infectious Meningitis","Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Adults Meningitis","ATLAS-I","Inclusion Criteria:\n\n* Fever (axillary temperature ≥37.8°C) followed by two or more of the following symptoms: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures OR\n* Fever accompanied by at least one meningeal irritation sign, such as neck stiffness, Kernig's sign, or Brudzinski's sign OR\n* Sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions\n\nExclusion Criteria:\n\n\\- Refusal to provide consent for study participation",{"count":110,"type":23},624,"6 Months","OBSERVATIONAL","Prospective, multicenter, observational clinical registry of adult patients with acute infectious meningitis across approximately 30 public and private hospitals in Brazil. The study will include adults, 18 years old and older, with suspected acute infectious meningitis. Data will be collected during hospitalization and post-discharge to evaluate clinical management, treatment and short and long-term outcomes. The study aims to generate real-world evidence on current practices and outcomes to support improvements in national care protocols.",[115,116,117,30],"Viral Meningitis","Bacterial Meningitis","Fungal Meningitis",[30,119,120,121,122,123],"Bacterial","Viral","Corticosteroids","Antibiotics","Fungal","2026-05-04",{"date":126,"type":50},"2026-05-07",{"date":128,"type":50},"2026-03-30",{"date":130,"type":23},"2027-02",{"name":132,"class":57},"Hospital Israelita Albert Einstein",3,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":66,"minAge":4,"maxAge":141,"enrollmentInfo":142,"targetDuration":144,"studyType":112,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":100},"100597742","prospective-clinical-registry-of-acute-treatment-and-long-term-assessment-of-children-meningitis-100597742","NCT07062445","Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis","ATLAS-II","Inclusion Criteria:\n\n* Fever (axillary temperature ≥37.8°C) followed by two or more of the following symptoms\\*: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures OR\n* Fever accompanied by at least one meningeal irritation sign, such as neck stiffness, Kernig's sign, or Brudzinski's sign OR\n* Sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions\n\n  * In children younger than two years, in addition to the presentations listed above, consider fever with any of the following: irritability, persistent crying, somnolence, or bulging fontanelle.\n\nExclusion Criteria:\n\n* Refusal to provide consent for study participation","17 Years",{"count":143,"type":23},600,"180 Days","Prospective, multicenter, observational clinical registry of pediatric patients with acute infectious meningitis across approximately 20 public and private hospitals in Brazil. The study will include children under 18 years of age with suspected acute infectious meningitis. Data will be collected during hospitalization and post-discharge to evaluate clinical management, treatment and short and long-term outcomes. The study aims to generate real-world evidence on current practices and outcomes to support improvements in national care protocols.",[30,147,115,117],"Bacterial Infections",[149,150,151,152,153,154],"meningitis","bacterial","virus","corticosteroids","antibiotics","fungal","2026-04-29",{"date":157,"type":50},"2026-05-05",{"date":159,"type":50},"2026-03-29",{"date":130,"type":23},{"name":132,"class":57},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":66,"minAge":169,"maxAge":19,"enrollmentInfo":170,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":100},"100413513","national-bacterial-meningitis-study-in-children-and-newborns-100413513","NCT04664569","National Bacterial Meningitis Study in Children and Newborns","National Observatory of Bacterial Meningitis in Children and Newborns","Inclusion Criteria:\n\n* clinical signs of meningitis, associated with positive cerebrospinal fluid (CSF) culture and\u002For positive CSF antigen testing (Escherichia coli K1, N. meningitidis serogroups B, A, C, Y and W-135, group B streptococci, Hib, or S. pneumoniae), and\u002For positive CSF polymerase chain reaction (PCR), and\u002For positive blood culture with CSF pleocytosis (\\> 10 cells\u002FµL).\n* purpura fulminans\n\nExclusion Criteria:\n\n\\-","1 Day",{"count":171,"type":23},10000,"Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data. The epidemiology of bacterialméningitis has changed in recent years, mainly owing to widespread use of different conjugate vaccines. The aim of this prospective national survey is to describe epidemiology of bacteria implicated in bacterial meningitis in children.",[30,174,175,176,177,178,179,180],"Children, Only","Pneumococcal Conjugate Vaccine","Meningococcal Vaccines","H. Influenzae Vaccine","Neonatal Infection","Antibiotic Treatment","Case Fatality Rate","2026-04-23",{"date":183,"type":50},"2026-04-28",{"date":185,"type":50},"2001-01-01",{"date":187,"type":23},"2030-01-01",{"name":189,"class":57},"Association Clinique Thérapeutique Infantile du val de Marne",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":205,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":100},"100626167","prediction-of-infectious-agents-in-the-biofire-filmarray-biomrieux-meningitisencephalitis-panel-based-on-clinical-syndrome-and-cerebrospinal-fluid-parameters-a-diagnostic-stewardship-proposal-100626167","NCT07432113","Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis\u002FEncephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.","Inclusion Criteria:\n\nPatients aged 18 years or older, of any gender.\n\nPresence of at least two of the following symptoms: fever, lethargy, altered level of consciousness, seizures, acute focal deficit, signs of meningeal irritation, or headache.\n\nSymptoms must have started within the last 30 days.\n\nObligatory presence of pleocytosis (CSF white blood cell count ≥ 5 cells\u002Fmm³).\n\nProvision of written Informed Consent (TCLE) by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Failure to sign the Informed Consent Form.\n\nClinical manifestations lasting more than 30 days.\n\nPatients under 18 years of age.\n\nPatients who have undergone neurosurgery within 30 days prior to the onset of symptoms (applies to both prospective and control groups).",{"count":197,"type":23},182,[26],"Background: Infections of the central nervous system (CNS) are associated with high morbidity, mortality, and high resource consumption. The BioFire FilmArray is a molecular diagnostic panel capable of identifying 14 pathogens in approximately one hour, including bacteria, viruses, and fungi. However, it is not yet widely available in the Brazilian public health system.\n\nObjective: The primary objective of this study is to evaluate the pre-test probability of positivity of the Biofire FilmArray bioMérieux Meningitis\u002FEncephalitis panel in patients with clinical syndrome of meningitis and\u002For encephalitis and pleocytosis (CSF ≥ 5 cells).\n\nAs secondary objectives, the study aims to:\n\nDetermine the clinical impact of using the panel through variables such as total hospital stay and length of stay in the intensive care unit.\n\nCompare the duration of antibiotic use in non-bacterial cases between groups. Compare the time to reduction of acyclovir use in etiologies without proven benefit.\n\nCompare the time for identification of the causative pathogen and mortality rates between the study groups.\n\nPerform a cost-effectiveness analysis of the test. Compare the request for imaging exams, such as brain MRI and CT scan, between the groups.\n\nMethods: This is a prospective, transversal, and multicenter study conducted at Santa Casa de Porto Alegre and Hospital Dom João Becker. Patients will be compared with a retrospective cohort used as a control group.",[30,201,75,202,203,204],"Encephalitic Infection","Meningitis, Fungal","Meningitis, Viral","Meningitis, Bacterial",[206,207,208,209,210],"filmarray","biofire","biofire filmarray","meningits","encephalitis","2026-02-18",{"date":213,"type":50},"2026-02-25",{"date":215,"type":23},"2026-03-16",{"date":217,"type":23},"2029-10-31",{"name":219,"class":57},"Federal University of Health Science of Porto Alegre",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":17,"sex":66,"minAge":227,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":230,"conditions":231,"keywords":289,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":100},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":171,"type":23},"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,30],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae",[290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":309,"type":50},"2026-01-22",{"date":311,"type":50},"2025-12-18",{"date":313,"type":23},"2027-09-30",{"name":315,"class":57},"Institut Pasteur du Cambodge",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":326,"conditions":327,"keywords":333,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":347},"100618485","optic-nerve-ultrasound-for-assessing-cerebral-inflammation-and-intracranial-hypertension-in-cerebral-pathologies-100618485","NCT07332234","Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies","Utility of Optic Nerve Ultrasonography in Assessing Cerebral Inflammation and Intracranial Hypertension in Patients With Cerebral Impairment","EICON","Inclusion Criteria:\n\n* Patients admitted into one of the specified wards of the involved hospitals\n* Patients aged 18-60 years\n* Suspected meningitis, encephalitis, stroke or cerebral tumors\n\nExclusion Criteria:\n\n* Age under 18 years or over 60 years old\n* Ocular lesions preventing ocular ultrasound (palpebral infections, cornean erosions, glaucoma, trauma)\n* Conditions preventing lumbar puncture (coagulation disorders, epidural abscesses, local infections)","60 Years",{"count":22,"type":23},"Timely detection of signs of raised intracranial pressure or persistent inflammation within the meninges can expedite therapeutic decisions improving the prognosis of patients with brain damage. Optic nerve ultrasonography provides a user-friendly, safe, low-cost, and non-invasive imaging method that can be easily deployed for ICU patient assessment. This study aims to evaluate the sensitivity and specificity of optic nerve ultrasound in estimating cerebral inflammation extension and cerebral edema in patients in the ICU. The working hypothesis is that optic nerve ultrasound is a useful tool in the rapid diagnosis of cerebral edema and the presence or persistence of cerebral inflammation, which can enable adapted and rapid therapeutic interventions.",[30,328,329,330,331,332],"Meningitis\u002FEncephalitis","Stroke","Ultrasound","Intracranial Hypertension","Cerebral Tumors",[334,335,336,30,75,329,337],"ONSD","Optic Nerve Sheath Diameter","Intracranial hypertension","Cerebral tumors","2026-01-09",{"date":340,"type":50},"2026-01-12",{"date":342,"type":50},"2025-12-01",{"date":344,"type":23},"2027-12-01",{"name":346,"class":57},"Spitalul Clinic de Boli Infecțioase și tropicale \"Dr. Victor Babeș\"",2,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":66,"minAge":4,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":100},"100477415","meningitis-burden-causes-screening-and-prevention-in-rural-northern-uganda-100477415","NCT05496673","Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda","Inclusion Criteria:\n\n* 1100 patients who present with meningitis or meningitis symptoms, regardless of age or vulnerably status are eligible for meningitis testing.\n* 10,000 HIV-infected patients presenting to LRRH, LRRH HIV Clinic (LIDC) or nearby outpatient clinics, regardless of age or vulnerability status, are eligible for CrAg screening.\n\nExclusion Criteria:\n\n* Patients who are found not to have meningitis after initial evaluation, or are found to have other alternative diagnoses that explain their symptoms, will be excluded.\n* HIV-negative patients without signs or symptoms of meningitis.",{"count":355,"type":23},11100,[26],"This study will investigate the burden, causes, diagnostics, treatments and preventive measures related to meningitis in northern Uganda. We hypothesize that understanding the burden of meningitis, risk factors, diagnostics, treatments and the preventive measures will provide information regarding the gaps in care that can be addressed in order to improve the continuum of meningitis care. we hypothesize that our data will support the advocacy for the implementation of routine vaccination for the prevention of bacterial meningitis and improving guidelines for Cryptococcal antigen (CrAg) screening for prevention of cryptococcal meningitis, which will save lives in Uganda.\n\nAim 1: To prospectively collect data on 1100 patients with meningitis and meningitis symptoms who were admitted to Lira Regional Referral Hospital (LRRH) to assess burden, etiologies, pathogenesis, and outcomes of meningitis using modern diagnostic testing not previously available in Uganda.\n\nAim 2: To perform CrAg screening of 10,000 HIV-positive patients to determine the prevalence of cryptococcal antigenemia (infection) and conduct a case control study to compare risk factors and outcomes among CrAg-positive patients and matched CrAg-negative controls based on age, sex, TB status, ART experience, CD4 count, and viral load.",[30],"2026-01-08",{"date":340,"type":50},{"date":362,"type":50},"2022-09-01",{"date":364,"type":23},"2031-09-01",{"name":366,"class":57},"University of Rochester",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":66,"minAge":373,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100617590","neuroendoscopic-surgery-with-ommaya-reservoir-implantation-vs-burr-hole-drainage-for-infantile-postmeningitis-subdural-lesions-superior-efficacy-critical-impact-of-surgical-timing-and-pathogenic-bacteria-as-risk-factors-for-progression-100617590","NCT07320599","Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural Lesions: Superior Efficacy, Critical Impact of Surgical Timing, and Pathogenic Bacteria as Risk Factors for Progression","Inclusion Criteria:\n\n\\- All enrolled children had received ≥3 weeks of standardized anti-infection therapy, including empirical or susceptibility-guided antibiotics administered intrathecal (post-lumbar puncture) or intravenous and dexamethasone administered intrathecal or intravenous. During conservative management, vital\u002Fneurological signs were closely monitored, with regular imaging to assess fluid thickness and empyema progression. Cranial ultrasound (primary modality, ≤3-day intervals) was performed, while CT\u002FMRI were conducted ≤weekly.\n\nExclusion Criteria:\n\n* subdural fluid collections secondary to viral meningitis; secondary collections with confirmed craniocerebral trauma history; diagnosed tuberculous subdural fluid collection; intracranial space-occupying lesions.","1 Month","1 Year",{"count":376,"type":23},100,"Globally, approximately 750,000 cases of infantile meningitis occur annually\\[1\\]. Clinical data show infantile postmeningitis subdural fluid collection (IPSFC) is the most common complication of infantile bacterial meningitis (IBM), with a progression rate of 30-60% (39% in standardized treatment cohorts)\\[2\\]. Pathogens, predominantly Escherichia coli and Streptococcus pneumoniae, account for 70% of IPSFC cases\\[3\\]. IPSFC progresses to subdural empyema (IPSE) in 3.7-17.6% of cases, with 87.1% of IPSE cases occurring in infants \\\u003C1 year old\\[4\\]. Collectively termed infantile postmeningitis subdural space lesions (IPSSL), these conditions impose the highest burden in Sub-Saharan Africa's \"Meningitis Belt\" and Southeast Asia\\[5\\]. IPSE progresses rapidly in infants, with a mortality rate of 18% and 50% of survivors developing neurological sequelae (e.g., epilepsy, motor\u002Fintellectual disability, sensory impairment)\\[6\\]. While spontaneously resolved IPSFC shows no significant sequelae, prolonged IPSE disrupts brain development, requires extended treatment, and incurs substantial familial burdens.\n\nCauses of IPSFC secondary to IBM include increased subdural capillary permeability (with plasma exudation), cerebrospinal fluid (CSF) circulation\u002Fabsorption disturbance, immature infantile blood-brain barrier (BBB), and underdeveloped arachnoid granulations\\[7\\]. IPSFC typically develops on days 7-10 of IBM and is staged by fluid thickness: Stage I (\\\u003C0.3 mm), Stage II (3-8 mm), Stage III (\\>8 mm)\\[8\\]. Uncontrolled IBM infection, due to inappropriate antibiotics, inadequate dosage, delayed treatment, or infantile immunocompromise, e.g., preterm infants, allows pathogens to invade and proliferate in the subdural space, inducing local secondary infection, inflammatory cell infiltration, and accumulation of pathogen metabolites\u002Fnecrotic tissue-ultimately progressing to IPSE\\[9\\]. Fibrinogen exudation and fibroblast activation may further form subdural fibrous cords, septa, purulent plaques, inflammatory pseudomembranes, and other fibro-inflammatory proliferative lesions (FIPLs)\\[10\\]. IPSE causes more severe mass\u002Ftoxic effects, requiring aggressive surgical intervention. Cranial MRI shows empyema cavity rim enhancement, heterogeneous internal signals due to fluid collection septa, and dural thickening.\n\nThe progression rate of IPSFC to IPSE ranges from 3.7% to 17.6%, influenced by IBM pathogen types, therapeutic intervention, and host immunity\\[11\\]. However, large-scale cohort studies on risk factors for this progression remain lacking. Early adequate antibiotic therapy reduces IPSFC incidence by nearly 50%, whereas delayed intervention may accelerate IPSFC onset (day 3-7) via unremitting meningeal permeability\\[12\\]. Inadequate antibiotic courses may promote persistent IPSFC progression with FIPLs formation. Some pediatric neurosurgeons advocate extending antibiotic therapy beyond 21 days for IPSFC to prevent progression to IPSE\\[13\\].\n\nDespite early antibiotic therapy reducing IBM mortality, IPSSL management remains challenging. A clinical study showed 22.4% of IPSFC cases required surgery, but occult inflammation in infants can prolong IPSFC up to 2 months\\[14\\]. Infantile unclosed fontanelles and cranial elasticity increase neurosurgical complication risks. Current consensus suggests asymptomatic\u002Fsmall-volume fluid collections (thickness \\\u003C5 mm) often resolve spontaneously, obviating intervention\\[15\\]. Ultrasound-guided subdural puncture (US-SP-AF) is the first-line invasive treatment, curing about 50% of infants acutely but with a 30-50% recurrence rate. Whether US-SP-AF reduces IPSFC-to-IPSE progression remains controversial. For US-SP-AF-resistant cases, minimally invasive burr hole irrigation (BHID) with silicone tube drainage (3-5 days) is used; BHID shows higher cure rates than US-SP-AF but still has a 20-33% recurrence rate in small cohorts\\[16\\].\n\nNeuroendoscopic technique allows rigid endoscope entry into the subdural space for visualized resection of pathological tissues, management of multiloculated cavities, adhesion lysis, and FIPLs irrigation. This approach directly targets the pathological substrate under vision, reducing residual lesions and recurrence rates compared to traditional methods. In adult cohorts, 6-month postoperative fluid collection recurrence rates are only 8% with neuroendoscopy, versus 33% with BHID\\[17\\]. However, neuroendoscopic exploration is technically demanding and equipment-dependent. The Ommaya reservoir offers advantages in postoperative management of cerebrospinal fluid-related disorders, including precise drainage, dynamic monitoring of disease progression, and local drug administration. However, it may be prone to catheter obstruction by pathological components\\[18\\].\n\nSevere IPSSL causes intracranial hypertension and neurodevelopmental impairment, requiring comprehensive pediatric neurosurgical and pharmacologic strategies. Treatment selection depends on IPSFC\u002FIPSE pathological features. Current stu",[30],[380],"infantile meningitis","2025-12-25",{"date":383,"type":50},"2026-01-06",{"date":385,"type":23},"2026-03-01",{"date":387,"type":23},"2027-06-30",{"name":389,"class":57},"Shengjing Hospital",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":66,"minAge":4,"maxAge":19,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":100},"100561031","bedside-ultrasound-on-the-effectiveness-of-lumbar-puncture-in-children-100561031","NCT06584864","Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children.","Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children - Open-label Randomized Trial","Inclusion Criteria:\n\n* children \\\u003C18 years of age\n* patients who are scheduled to undergo lumbar puncture\n* consent of legal guardian\n\nExclusion Criteria:\n\n* infection of skin and tissues in the area of planned puncture\n* developmental defects of the spine and spinal cord\n* lack of consent of legal guardian\n* contraindications to lumbar puncture",{"count":398,"type":23},120,[26],"The aim of the study is to assess the influence of ultrasound examination of the lumbar spinal canal on the effectiveness of lumbar puncture. An open-label, randomized interventional study.",[30,402],"Pediatric Disorder","2025-07-29",{"date":405,"type":50},"2025-07-30",{"date":407,"type":50},"2024-03-01",{"date":409,"type":23},"2026-06-01",{"name":411,"class":57},"Medical University of Warsaw",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":66,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":24,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":4},"100578448","neonatal-comfort-seat-allowing-safe-lumbar-puncture-and-minimizing-failure-a-randomized-controlled-trial-100578448","NCT06811428","Neonatal Comfort Seat Allowing Safe Lumbar Puncture and Minimizing Failure: a Randomized Controlled Trial","NeoCALM","Inclusion Criteria:\n\n* Late preterm (34 + weeks) Gestational Age to Term (42+ weeks GA)\n* Weight of 2.5 - 5 kg\n\nExclusion Criteria:\n\n* Any contraindication to having a lumbar punture procedure","0 Days","28 Days",{"count":422,"type":23},68,[26],"A research trial which compares standard of care against employing a novel device for immobilization of babies undergoing upright LP, the present working name for the device is LP Comfort Seat (LPCS).\n\nThe research question is:\n\nP: In late-preterm to term babies who are 0-28 days and undergoing LP for R\u002FO Sepsis I: Is the LPCS more effective C: Than human\u002FRN assisted upright positioning O: In generating a higher rate of first attempt LP success\n\nPrimary outcome measure is first attempt LP success (any evidence of CSF which is diagnostically useful by content and volume)\n\nSecondary outcome measures could include\n\n1. A qualitatively unadulterated tap (no blood) although as you know this is hard to control even with perfect positioning and technique and single pass\n2. A difference in FLACC score as measure of overall pain\u002Fcomfort between test and control",[426,30],"Sepsis",[428,429,430,431,432,30,426],"Lumbar puncture","Seating device","Positioning device","Newborn","Neonatal","2025-01-31",{"date":435,"type":50},"2025-02-06",{"date":437,"type":23},"2025-03-01",{"date":439,"type":23},"2026-04-01",{"name":441,"class":57},"Joel Cox",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":449,"targetDuration":451,"studyType":112,"phases":4,"briefSummary":452,"conditions":453,"keywords":456,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":464,"leadSponsor":466,"locationsCount":100},"100555335","evaluation-of-the-levels-of-calcitonin-gene-related-peptide-and-substance-p-100555335","NCT06510751","Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P","Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P in Patients With Post-operative Meningitis","Inclusion Criteria:\n\n* Patients aged 18 years and over\n* Patients followed up in the intensive care unit with suspected meningitis\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients with suspected meningitis in the intensive care unit who have not undergone neurosurgical operation and do not have CSF drainage catheter",{"count":450,"type":23},51,"16 Months","In cases of meningitis caused by external ventricular catheters (EVDs), which are the most commonly placed intracranial catheters that can lead to central nervous system infection through contamination\u002Fcolonisation, the diagnosis may not be differentiated by either clinical signs and symptoms or conventional cerebrospinal fluid (CSF) tests. Therefore, due to the limitations in diagnosis and prognostic prediction of EVD-induced meningitis and the high mortality\u002Fmorbidity rates of the disease, markers with high sensitivity and specificity in post-operative meningitis are needed. Calcitonin gene-related peptide (CGRP), a neuropeptide, has been shown to increase when C or Aδ sensory fibres are damaged or in the presence of inflammation in tissues adjacent to the fibres. CGRP is localised in nociceptive nerve terminals together with another neuropeptide, substance P, which has similar biological effects. There are very few studies investigating how CGRP levels in CSF and serum change in bacterial meningitis. Although it is thought that nociception and neuroimmune interactions affect meningeal antibacterial host defence, that nociceptors signal via CGRP to meningeal immune cells during infection, and that this neuroimmune axis exacerbates bacterial meningitis by weakening host defence, it is not yet clear how CGRP and substance P levels affect disease prognosis. This study will evaluate the utility of CGRP and substance P levels as biomarkers to assess diagnosis and treatment response in patients with post-operative meningitis followed in the intensive care unit.",[30,454,455],"Diagnosis","Prognosis",[457,458,459],"Postoperative meningitis","Calcitonin gene-related peptide","Substance P","2024-07-15",{"date":462,"type":50},"2024-07-19",{"date":407,"type":50},{"date":465,"type":23},"2025-08-30",{"name":467,"class":57},"Melike Cengiz",{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":478,"conditions":479,"keywords":488,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":500,"locationsCount":502},"100317883","central-nervous-system-infections-in-denmark-100317883","NCT03418441","Central Nervous System Infections in Denmark","Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark","DASGIB","Definitions of central nervous system infections:\n\nFor all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.\n\nViral meningitis inclusion criteria\n\n\\- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)\n\nand\n\nCerebrospinal fluid leukocytes\\>10 cells\u002Fml\n\nPatients with viral meningitis with undetermined pathogen have to have:\n\n* CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nBacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)\n\nand\n\nProven bacterial aetiology (CSF or blood culture\u002FDNA based technology or antigen tests)\n\nPatients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:\n\n\\- CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nEncephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status \\>24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093\u002Fcid\u002Fcit458.).\n\nEncephalitis exclusion criteria\n\n\\- We exclude cases of proven or suspected autoimmune encephalitis.\n\nPrimary brain abscess inclusion criteria\n\n\\- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)\n\nand\n\n\\- Proven microbiological aetiology by culture\u002FDNA-based technology from pus from brain abscess or blood or CSF\n\nor\n\n\\- Aspiration of pus from the brain abscess\n\nor\n\n\\- Response to antimicrobial treatment\n\nor\n\n\\- Tumour ruled out\n\nor\n\n\\- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.\n\nLyme neuroborreliosis inclusion criteria\n\n\\- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)\n\nand\n\n\\- CSF pleocytosis\\>10 leukocytes\u002FmL\n\nand\n\n\\- Positive intrathecal B.burgdorferi antibody production index.\n\nNeurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)\n\nand either\n\n\\- Positive syphilis serology in serum combined with CSF leukocytes\\>10\u002FmL\n\nor\n\n\\- CSF syphilis antibodies.",{"count":477,"type":23},1900,"The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\\>17 years of age) patients with community-acquired CNS infections diagnosed and\u002For treated at departments of infectious diseases in Denmark since 1st of January 2015.",[480,116,115,481,75,482,483,484,485,486,487,30],"Central Nervous System Infections","Aseptic Meningitis","Brain Abscess","Neuroborreliosis","Neurosyphilis","Lyme Disease","Tertiary Syphilis","Cerebral Abscess",[489,490,480,30,75,491,492,483,484,493],"Nationwide prospective observational cohort study","Epidemiology","Brain abscess","Lyme disease","Tertiary syphilis","2024-05-15",{"date":496,"type":50},"2024-05-16",{"date":498,"type":50},"2015-01-01",{"date":187,"type":23},{"name":501,"class":57},"Aalborg University Hospital",8,{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":66,"minAge":169,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":100},"100125506","lebanese-interhospital-pneumococcal-surveillance-program-100125506","NCT00901602","Lebanese Interhospital Pneumococcal Surveillance Program","Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)","LIPSP","Inclusion Criteria:\n\n* Samples included in the study are those that are:\n\n  * culture proven\n  * invasive pneumococcal infections\n  * in patients of all ages admitted to different hospitals all over Lebanon\n* Acceptable samples include:\n\n  * positive isolates from blood\n  * cerebrospinal fluid\n  * other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration\n\nExclusion Criteria:\n\n* non S. pneumoniae isolates",{"count":512,"type":23},700,"Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.",[515,30,426,516],"Pneumonia","Bacteremia",[518,519,520,149,521,522,523],"streptococcus pneumoniae","pneumococcus","pneumonia","serotypes","bacteremia","sepsis","2023-02-02",{"date":526,"type":50},"2023-02-03",{"date":528,"type":4},"2005-10",{"date":530,"type":23},"2030-10",{"name":532,"class":57},"American University of Beirut Medical Center"]